Browsing by Author "Germing, U."
Now showing 1 - 20 of 79
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE(Ferrata Storti Foundation, 2016)
;Schaab, R. ;Ganster, Christina ;Dierks, Sascha ;Parra, Tallo M. ;Martin, R. ;Germing, U. ;Platzbecker, Uwe; ;Lange, F. ;Kroeger, Nicolaus M. ;Doehner, Konstanze ;Glass, Bertram; - Some of the metrics are blocked by yourconsent settings454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial(Karger, 2013)
;Mossner, Maximilian ;Nowak, D. ;Platzbecker, Uwe ;Giagounidis, Aristoteles A. N. ;Goetze, K. ;Letsch, Anne; ;Shimeshan, K. ;Schlenk, Richard F. ;Kohlmann, A. ;Haferlach, Torsten ;Bug, G. ;Luebbert, Michael ;Ganser, Arnold ;Jann, J-C ;Oblaender, Julia ;Fey, Stephanie ;Hofmann, W-K ;Germing, U.Nolte, F. - Some of the metrics are blocked by yourconsent settingsAdequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients(Pergamon-elsevier Science Ltd, 2005)
;Steidl, Christian ;Steffens, Rainer ;Gassmann, W.; ;Hilgers, Ralf-Dieter ;Germing, U.; In myelodysplastic syndromes (MDS), the karyotype is one of the most significant prognostic markers with profound impact on differential diagnosis and therapeutic decisions. In a retrospective study, we examined karyotypes of bone marrow specimens of an oligocentric cohort comprising 529 patients with MDS to address the question how many metaphases need to be analyzed to detect even small cell clones with an appropriate expenditure. We found a statistically significant difference of the frequency of normal karyotypes in the patient group with 19 or less analyzed metaphases compared to the group with 20 or more metaphases analyzed (56% versus 47%, p=0.041). Furthermore, we demonstrate that the analysis of 25 or more metaphases can further improve the sensitivity of karyotype analysis and leads to the identification of additional clinically relevant abnormal clones or subclones in a substantial proportion of patients. In summary, our data suggest the examination of at least 20 metaphases in MDS. (c) 2005 Elsevier Ltd. All rights reserved. - Some of the metrics are blocked by yourconsent settingsApplicability of comprehensive cytogenetic analysis of peripheral blood of MDS patients by combined FISH and SNP-array analysis(Pergamon-elsevier Science Ltd, 2013)
;Ganster, Christina; ; ; ;Schanz, J. ;Goetze, K. S. ;Giagounidis, Aristoteles A. N. ;Germing, U. ;Platzbecker, Uwe - Some of the metrics are blocked by yourconsent settingsAttempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems(Pergamon-elsevier Science Ltd, 2009)
;Noesslinger, T. ;Tuechler, Heinz ;Makrai, A. ;Germing, U. ;Sperr, Wolfgang R. ;Krieger, Otto; ;Luebbert, Michael ;Stauder, Reinhard ;Giagounidis, Aristoteles A. N. ;Valent, PeterPfeilstoecker, Michael - Some of the metrics are blocked by yourconsent settingsCharacterization and prognostic significance of cytogenetically unrelated clones in myelodysplastic syndromes and acute myeloid leukemia(Karger, 2011)
;Schanz, J. ;Kessels, S. ;Haferlach, Claudia ;Bardi, Georgia ;Gourgouveli, E. ;Slovak, Marilyn L. ;Johansson, Bertil ;Ohyashiki, Kazuma ;Sole, Francesco ;Eclache, V. ;Wimzal, Friedrich ;Pfeilstoecker, Michael ;Noesslinger, T. ;Fonatsch, Christa ;Luebbert, Michael ;Giagounidis, Aristoteles A. N. ;Stauder, Reinhard ;Krieger, Otto ;Prescher, Gabriele; ;Greenberg, Peter L. ;Le Beau, Michelle M. ;Bennett, John M. ;Germing, U. - Some of the metrics are blocked by yourconsent settingsCHARACTERIZATION OF FLT3 MUTATIONS AT DIAGNOSIS, REFRACTORY DISEASE OR RELAPSE IN AML PATIENTS TREATED WITH MIDOSTAURIN WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS(Ferrata Storti Foundation, 2017)
;Schmalbrock, L. K. ;Theis, F. ;Bullinger, Lars ;Weber, Daniela ;Gaidzik, Verena I. ;Paschka, Peter ;Teleanu, M.-V. ;Fiedler, Walter ;Salih, Helmut R.; ;Germing, U. ;Luebbert, Michael ;Thol, Felicitas ;Heuser, M. ;Larson, R. A. ;Ganser, Arnold ;Schlenk, Richard F. ;Stone, R. M. ;Doehner, HartmutDoehner, Konstanze - Some of the metrics are blocked by yourconsent settingsCLINICAL AND PROGNOSTIC CHARACTERISTICS OF 484 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME (T-MDS) OR ACUTE MYELOID LEUKEMIA (T-AML)(Ferrata Storti Foundation, 2008)
;Kuendgen, A. K.; ;Giagounidis, Aristoteles A. N. ;Blum, S. ;Fischer, S. ;Platzbecker, Uwe ;Schlenk, Richard F.; ;Valent, Peter ;Stadler, M. ;Stauder, Reinhard ;Krieger, Otto ;Goetze, K. ;Hofmann, Wolf-Karsten ;Ganser, Arnold ;Mende, Claudia ;Haas, Rainer ;Gattermann, NorbertGerming, U. - Some of the metrics are blocked by yourconsent settingsClinical features, treatment and prognosis in patients with MDS and monosomy 7(Pergamon-elsevier Science Ltd, 2013)
;Schanz, J. ;Nachtkamp, K. ;Germing, U. ;Haas, P. ;Luebbert, Michael ;Mueller-Thomas, Catharina ;Goetze, K. ;Platzbecker, Uwe ;Nolte, F. - Some of the metrics are blocked by yourconsent settingsClinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group(Nature Publishing Group, 2016)
;Theis, F. ;Corbacioglu, Andrea ;Gaidzik, Verena I. ;Paschka, Peter ;Weber, Daniela ;Bullinger, Lars ;Heuser, M. ;Ganser, Arnold ;Thol, Felicitas ;Schlegelberger, Brigitte ;Goehring, Gudrun ;Koehne, C-H ;Germing, U. ;Brossart, Peter ;Horst, H-A; ;Goetze, K. ;Ringhoffer, Mark ;Fiedler, Walter ;Nachbaur, D. ;Kindler, Thomas ;Held, Gerhard ;Luebbert, Michael ;Wattad, Mohammed ;Salih, H. R. ;Krauter, Juergen ;Doehner, Hartmut ;Schlenk, Richard F.Doehner, Konstanze - Some of the metrics are blocked by yourconsent settingsCLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)(Ferrata Storti Foundation, 2017)
;Theis, F. ;Corbacioglu, Andrea ;Gaidzik, Verena I. ;Paschka, Peter ;Weber, Daniela ;Bullinger, Lars ;Schlegelberger, Brigitte ;Goehring, Gudrun ;Koehne, Claus-Henning ;Kraemer, Doris ;Germing, U. ;Brossart, Peter ;Horst, H.-A.; ;Goetze, K. ;Ringhoffer, Mark ;Fiedler, Walter ;Nachbaur, D. ;Kindler, Thomas ;Held, Gerhard ;Luebert, Michael ;Wattad, Mohammed ;Salih, H. R. ;Krauter, Juergen ;Heuser, M. ;Thol, Felicitas ;Ganser, Arnold ;Doehner, Hartmut ;Schlenk, Richard F.Doehner, Konstanze - Some of the metrics are blocked by yourconsent settingsCLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS(Ferrata Storti Foundation, 2017)
;Schmalbrock, L. K. ;Cocciardi, S. ;Dolnik, A. ;Agrawal, M. ;Theis, F. ;Jahn, N. ;Blaette, T. J. ;Gaidzik, Verena I. ;Paschka, Peter ;Fiedler, Walter ;Salih, Helmut R.; ;Germing, U. ;Luebbert, Michael ;Thol, Felicitas ;Heuser, M. ;Larson, R. A. ;Ganser, Arnold ;Schlenk, Richard F. ;Stone, R. M. ;Doehner, Hartmut ;Doehner, KonstanzeBullinger, Lars - Some of the metrics are blocked by yourconsent settingsCorrelation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS.(Amer Soc Hematology, 2005)
; ;Steidl, Christian ;Schanz, J. ;Schabla, R. ;Pfeilstocker, M. ;Nosslinger, T.; ;Kuendgen, A. ;Lubbert, M. ;Kunzmann, B. ;Giagounidis, Aristoteles A. N. ;Auls, C.; ;Krieger, Otto ;Fonatsch, Christa ;Valent, Peter ;Stauder, ReinhardGerming, U. - Some of the metrics are blocked by yourconsent settingsCytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes(Karger, 2016)
; ;Platzbecker, Uwe ;Mueller-Thomas, Catharina ;Goetze, K. ;Germing, U. ;Bruemmerndorf, T. H. ;Nolte, F. ;Hofmann, W-K ;Giagounidis, Aristoteles A. N. ;Luebbert, Michael ;Greenberg, Peter L. ;Bennett, John M. ;Sole, Francesco ;Mallo, Mar ;Slovak, Marilyn L. ;Ohyashiki, Kazuma ;Le Beau, Michelle M. ;Tuechler, Heinz ;Pfeilstoecker, Michael ;Noesslinger, T.; ; ;Aul, Carlo ;Stauder, Reinhard ;Sperr, Wolfgang R. ;Valent, Peter ;Fonatsch, Christa; ; Schanz, J. - Some of the metrics are blocked by yourconsent settingsCytogenetic diagnostics of CD34+peripheral blood cells in MDS: Results from the multicenter German prospective diagnostic CD34+FISH study(Karger, 2012)
; ;Schanz, J. ;Goetze, K. ;Mueller-Thomas, Catharina ;Platzbecker, Uwe ;Ganster, Christina; ;Metz, M. ;Detken, Sven ;Seraphn, J. ;Bruemmendorf, Tim Hendrik ;Giagounidis, Aristoteles A. N. ;Germing, U. ;Jentsch-Ullrich, Kathleen ;Boehme, A. ;Bug, G. ;Ottmann, Oliver G. ;Schafhausen, Philippe ;Stadler, M. ;Hofmann, W.-K ;Schmidt, B. ;Lubbert, M. ;Schlenk, Richard F. ;Blau, Igor W.; - Some of the metrics are blocked by yourconsent settingsCytogenetic metaphase analysis in myelodysplastic syndromes - Diagnostic accuracy is significantly dependent on the number of metaphases analyzed.(Amer Soc Hematology, 2003)
;Steidl, Christian; ;Germing, U.; - Some of the metrics are blocked by yourconsent settingsCytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial(Karger, 2016)
; ;Germing, U. ;Schuler, E.; ;Platzbecker, Uwe ;Nolte, F. ;Hofmann, W-K ;Giagounidis, Aristoteles A. N. ;Goetze, K. ;Luebbert, Michael ;Schlenk, Richard F. ;Schanz, J.; ; ;Ganser, Arnold ;Letsch, Anne ;Schafhausen, Philippe ;Bug, G. ;Bruemmendorf, Tim Hendrik ;Haas, Rainer; - Some of the metrics are blocked by yourconsent settingsCytogenetic monitoring of response and karyotype evolution in low-risk MDS patients treated in the LeMon5 study(Karger, 2013)
; ;Platzbecker, Uwe ;Nolte, F. ;Giagounidis, Aristoteles A. N. ;Goetze, K.; ;Schanz, J. ;Germing, U. - Some of the metrics are blocked by yourconsent settingsCytogenetic response and karyotype evolution in the LeMon5 study: Update of recent findings(Pergamon-elsevier Science Ltd, 2013)
; ;Platzbecker, Uwe ;Nolte, F. ;Giagounidis, Aristoteles A. N. ;Goetze, K.; ;Schanz, J. ;Germing, U. - Some of the metrics are blocked by yourconsent settingsCytogenetic update of the LE MON 5 Study(Karger, 2012)
; ; ;Schanz, J. ;Platzbecker, Uwe ;Giagounidis, Aristoteles A. N. ;Nolte, F. ;Goetze, K. ;Germing, U.